Novartis has earned a spot among the world’s top performers, ranking #19 in TIME and Statista’s World’s Best Companies 2026 – a significant rise from #114 last year. The recognition reflects progress across three critical areas: business performance, workplace experience, and sustainability.

Novartis has reached the highest performance tier in the CCLA Corporate Mental Health Benchmark, recognizing a comprehensive approach to workplace mental health, wellbeing and employee support.

Novartis is working with community partners to bring heart disease and cancer screening, information and support closer to where people are.

Nazem Atassi, Development Unit Head for Neuroscience and Gene Therapies, Global Drug Development.

Millions of people around the world continue to face barriers to prevention, diagnosis and treatment for chronic diseases such as heart disease and cancer. To help address these gaps, Novartis is scaling its community health programs from 11 to more than 30 countries by 2030, working alongside local partners to connect more people to care.

Christian Diehl, Chief Data & Digital Officer, Novartis Biomedical Research

For more than three decades, Novartis has been committed to the fight against malaria, one of the world's deadliest diseases. Fortune has now recognized that work by naming our malaria program to its 2026 Change The World list.

Novartis chemists receive “Heroes of Chemistry” honor from the American Chemical Society for work on CML drug discovery.

Novartis has announced new long-term Social Impact & Sustainability (SI&S) targets and goals, reinforcing our commitment to go beyond breakthroughs to maximize the impact of our medicines to support inclusive, resilient healthcare systems worldwide.

For a quarter of a century, Novartis and The Max Foundation have worked together to help people living with cancer in low- and middle-income countries access the care they need.